Axogen Inc vs BlackRock TCP Capital Corp — how do they compare? Axogen Inc trades at $49.81 (market cap $2.61B), while BlackRock TCP Capital Corp trades at $3.96 (market cap $327.64M). The key difference: Axogen Inc is far larger — about 8× BlackRock TCP Capital Corp's market cap, and BlackRock TCP Capital Corp pays a 19.46% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | TCPC | |
|---|---|---|
Market Cap | $2.61B | $327.64M |
Sector | Technology | Financials |
52-Week High | $48.48 | $7.26 |
52-Week Low | $14.16 | $3.13 |
Enterprise Value | $2.52B | — |
Dividend Yield | — | 19.46% |
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
TCPC trades at $3.92, down 0.51% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent Q2 2026 earnings beat expectations at $0.22 per share, and the company completed a $523 million portfolio sale to reduce leverage. However, fundamentals show negative revenue and net income trends, with a high P/S ratio of 70.7 but a discounted P/B of 0.59.
The outlook is mixed: strategic actions and dividend yield near 8.7% offer value, but declining revenue, negative ROE/ROA, and class-action lawsuits pose significant risks. Analyst consensus is cautious with 30.8% buy ratings, suggesting limited upside without fundamental improvement.
Trailing returns across standard periods
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →BlackRock TCP Capital Corp is a finance company specializing in middle-market lending. It aims for high returns through income and capital appreciation while prioritizing principal protection. The company invests in debt securities and earns revenue from interest payments, fees, and some equity appreciation.
Read more on TCPC →